FGP
TBPH icon

Freestone Grove Partners’s Theravance Biopharma TBPH Stock Holding History

Freestone Grove Partners’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-26,647
Closed -$432K – 1311
2026
Q1 		$432K Buy
+26,647
New +$471K ﹤0.01% 631

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
ICM
Irenic Capital Management New York $2.08B AUM 19.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Freestone Grove Partners's TBPH Position: Q2 2026 in Review

Freestone Grove Partners sold out of Theravance Biopharma (TBPH) in Q2 2026, closing a stake of 26,647 shares — an estimated $432K sold.

Freestone Grove Partners first reported a position in TBPH in Q1 2026 and held it in 1 quarter. The position peaked at $432K in Q1 2026. 181 funds tracked by Wall St. Rank hold TBPH as of Q2 2026.

  • Freestone Grove Partners reported no remaining Theravance Biopharma position as of Q2 2026 after selling out during the quarter.
  • Freestone Grove Partners sold 26,647 Theravance Biopharma shares in Q2 2026, an estimated $432K.
  • Freestone Grove Partners first reported a position in Theravance Biopharma in Q1 2026 and held it in 1 quarter.
  • Freestone Grove Partners's Theravance Biopharma position peaked at $432K in Q1 2026.
  • 181 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2026.

Based on Freestone Grove Partners's 13F filing for Q2 2026, filed 14 Aug 2026.